293 related articles for article (PubMed ID: 28265738)
1. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
[TBL] [Abstract][Full Text] [Related]
2. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
3. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
4.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
[TBL] [Abstract][Full Text] [Related]
6. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
7. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
8. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.
Miao Z; Ren G; Jiang L; Liu H; Webster JM; Zhang R; Namavari M; Gambhir SS; Syud F; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1977-84. PubMed ID: 21761266
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
10. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
[TBL] [Abstract][Full Text] [Related]
11. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
12. Development of
Woo SK; Jang SJ; Seo MJ; Park JH; Kim BS; Kim EJ; Lee YJ; Lee TS; An GI; Song IH; Seo Y; Kim KI; Kang JH
J Nucl Med; 2019 Jan; 60(1):26-33. PubMed ID: 29777007
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
14. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382
[TBL] [Abstract][Full Text] [Related]
16. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.
Ren G; Zhang R; Liu Z; Webster JM; Miao Z; Gambhir SS; Syud FA; Cheng Z
J Nucl Med; 2009 Sep; 50(9):1492-9. PubMed ID: 19690041
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
18. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
[TBL] [Abstract][Full Text] [Related]
20. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]